Trial intelligence / Profile preview

VAGEL study of intravaginal Lactobacillus-derived gel for cervical intraepithelial neoplasia

jRCTs032260681

Key facts

Status
Recruiting
Start
Nov 2026
Countries
1
Sponsor
WELLBEING Yokohama
Drugs
Lactobacillus-derived component-containing intravaginal gel
Conditions
cervical intraepithelial neoplasia (CIN)
01

Overview

Open-label, single-arm trial of Lactobacillus-derived component-containing intravaginal gel in cervical intraepithelial neoplasia (CIN), sponsored by WELLBEING Yokohama. Primary endpoint: Proportion of participants showing regression of cervical intraepithelial neoplasia at 24 weeks. Started Nov 2026; status: recruiting.

02

Design

1 arm
Study design
Non-randomizedOpen-labelSingle group
  • Single treatment arm

    Participants receive Lactobacillus-derived component-containing intravaginal gel for 24 weeks.

03

Who it enrols

Premenopausal women aged 20 to 54 years with histopathologically confirmed CIN1 or CIN2 are eligible. Participants must not have used treatments that may affect the vaginal microbiota within 2 weeks before enrollment and must be able to self-administer the intravaginal gel. Pregnant or breastfeeding women, women planning pregnancy, those with immunodeficiency including HIV infection, prior cervical conization or hysterectomy, severe underlying illness, inability to self-administer the gel, or recent participation in another interventional trial are excluded.

04

Endpoints

Primary

  • Proportion of participants showing regression of cervical intraepithelial neoplasia at 24 weeks

Secondary

  • Changes in vaginal microbiome composition

  • Changes in the relative abundance of Lactobacillus species

  • Changes in alpha diversity

  • Changes in Community State Type

  • Changes in vaginal pH

  • Changes in HPV-related parameters

  • Changes in cytological findings

  • Association between baseline vaginal microbiota and CIN regression

Beyond the preview

Go deeper on jRCTs032260681.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCTs032260681.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call